Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
Key findings included the reprogramming of FOXA1 and the identification of ARNTL as a novel therapeutic target, with ongoing research into epigenetic biomarkers and drug combinations like enzalutamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback